Physician profile
Madiha Haque
NPI 1467974170
$977.98
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $66.79 · 2021: $266 · 2022: $256 · 2023: $239 · 2024: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $201.00 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $112.49 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $97.40 | 2022-2024 | Eliquis |
| Glaxosmithkline, LLC. | $83.07 | 2020-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.61 | 2022-2024 | Jardiance |
| Novo Nordisk INC | $59.78 | 2022-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $58.25 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $52.06 | 2020-2023 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $48.00 | 2024 | Entyvio |
| Amgen INC. | $44.11 | 2023-2024 | Repatha |
| Lilly USA, LLC | $24.83 | 2022 | |
| Amarin Pharma, INC. | $24.15 | 2021 | |
| Janssen Pharmaceuticals, INC | $24.12 | 2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.31 | 2020 | |
| Dexcom, INC. | $22.04 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $19.67 | 2021 | |
| Biogen, INC. | $18.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madiha Haque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.